DCIS patients receiving anastrozole reported symptoms different from those receiving

[News]

Both groups reported similar quality of life. Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were...

More... (http://www.medicalnewstoday.com/releases/304026.php)